Literature DB >> 2414313

Nuclear membrane-staining antinuclear antibody in patients with primary biliary cirrhosis.

A Ruffatti, P Arslan, A Floreani, G De Silvestro, A Calligaro, R Naccarato, S Todesco.   

Abstract

An antinuclear antibody specific for nuclear membrane (ANMA) was observed by the immunofluorescence method in sera from patients with primary biliary cirrhosis (PBC). ANMA was present in 18 of 63 PBC sera (28.5) and in 1 of 431 control sera (0.2%). Its reaction appeared as a thin fluorescent ring confined to the nuclear envelope and was more evident when the sera were highly diluted and the fluorescence, due to frequently associated antimitochondrial antibody, faded. The ANMA fluorescent pattern was confirmed by indirect immunoperoxidase staining. ANMA was seen on both tissue cryostat sections and HEp-2 cells. It was a poorly or non-complement-fixing IgG, specific for an antigen resistant to DNase I, RNase, and trypsin. The significance of its presence in PBC in unknown at present. Identification of its antigen with one of the centromeric antigens is suggested.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2414313     DOI: 10.1007/bf00918255

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  15 in total

1.  Antinuclear factor and other antibodies in blood and liver diseases.

Authors:  E J HOLBOROW; G L ASHERSON; G D JOHNSON; R D BARNES; D S CARMICHAEL
Journal:  Br Med J       Date:  1963-03-09

Review 2.  Immunopathology of liver disease.

Authors:  D Doniach; G Walker
Journal:  Prog Liver Dis       Date:  1972

3.  Antinuclear antibodies in primary biliary cirrhosis.

Authors:  F Powell; A L Schroeter; E R Dickson
Journal:  Lancet       Date:  1984-02-04       Impact factor: 79.321

4.  Primary biliary cirrhosis with scleroderma, Raynaud's phenomenon and telangiectasia. New syndrome.

Authors:  T B Reynolds; E K Denison; H D Frankl; F L Lieberman; R L Peters
Journal:  Am J Med       Date:  1971-03       Impact factor: 4.965

5.  Rheumatic disorders in primary biliary cirrhosis.

Authors:  A K Clarke; R M Galbraith; E B Hamilton; R Williams
Journal:  Ann Rheum Dis       Date:  1978-02       Impact factor: 19.103

6.  Comparison of the complement-fixing activity of antinuclear antibodies in lupus nephritis, mixed connective tissue disease, and scleroderma.

Authors:  M D Parker; R A Turner
Journal:  Arthritis Rheum       Date:  1976 Sep-Oct

7.  Anticentromere antibody in primary biliary cirrhosis.

Authors:  R M Bernstein; M E Callender; J M Neuberger; G R Hughes; R Williams
Journal:  Ann Rheum Dis       Date:  1982-12       Impact factor: 19.103

8.  Nuclei from rat liver: isolation method that combines purity with high yield.

Authors:  G Blobel; V R Potter
Journal:  Science       Date:  1966-12-30       Impact factor: 47.728

9.  Is mitochondrial antibody diagnostic of primary biliary cirrhosis?

Authors:  L E Munoz; H C Thomas; P J Scheuer; D Doniach; S Sherlock
Journal:  Gut       Date:  1981-02       Impact factor: 23.059

10.  Distribution of kinetochore (centromere) antigen in mammalian cell nuclei.

Authors:  Y Moroi; A L Hartman; P K Nakane; E M Tan
Journal:  J Cell Biol       Date:  1981-07       Impact factor: 10.539

View more
  13 in total

1.  Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis.

Authors:  E I Rigopoulou; E T Davies; A Pares; K Zachou; C Liaskos; D-P Bogdanos; J Rodes; G N Dalekos; D Vergani
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

Review 2.  Primary biliary cirrhosis: nature of autoantigens.

Authors:  M F Bassendine; S J Yeaman
Journal:  Springer Semin Immunopathol       Date:  1990

3.  The 210-kD nuclear envelope polypeptide recognized by human autoantibodies in primary biliary cirrhosis is the major glycoprotein of the nuclear pore.

Authors:  J C Courvalin; K Lassoued; E Bartnik; G Blobel; R W Wozniak
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

Review 4.  Primary biliary cirrhosis: what do autoantibodies tell us?

Authors:  Chao-Jun Hu; Feng-Chun Zhang; Yong-Zhe Li; Xuan Zhang
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

5.  The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.

Authors:  Gideon M Hirschfield; Jessica K Dyson; Graeme J M Alexander; Michael H Chapman; Jane Collier; Stefan Hübscher; Imran Patanwala; Stephen P Pereira; Collette Thain; Douglas Thorburn; Dina Tiniakos; Martine Walmsley; George Webster; David E J Jones
Journal:  Gut       Date:  2018-03-28       Impact factor: 23.059

6.  Autoantibodies to 200 kD polypeptide(s) of the nuclear envelope: a new serologic marker of primary biliary cirrhosis.

Authors:  K Lassoued; M N Guilly; C Andre; M Paintrand; D Dhumeaux; F Danon; J C Brouet; J C Courvalin
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

Review 7.  Primary biliary cirrhosis and the nuclear pore complex.

Authors:  Carolina Duarte-Rey; Dimitrios Bogdanos; Chen-Yen Yang; Krista Roberts; Patrick S C Leung; Juan-Manuel Anaya; Howard J Worman; M Eric Gershwin
Journal:  Autoimmun Rev       Date:  2012-04-01       Impact factor: 9.754

8.  Complement profile in primary biliary cirrhosis.

Authors:  M Schlesinger; C Benbassat; Y Shoenfeld
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

9.  Diagnostic value of anti-gp210 antibodies in primary biliary cirrhosis: a case-based review.

Authors:  Florent Valour; Stéphane Durupt; Safia Khenifer; Isabelle Durieu
Journal:  BMJ Case Rep       Date:  2013-06-26

10.  Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis.

Authors:  Gary L Norman; Chen-Yen Yang; Heather P Ostendorff; Zakera Shums; Mark J Lim; Jinjun Wang; Amany Awad; Gideon M Hirschfield; Piotr Milkiewicz; Donald B Bloch; Kenneth J Rothschild; Christopher L Bowlus; Iannis E Adamopoulos; Patrick S C Leung; Harry J Janssen; Angela C Cheung; Catalina Coltescu; M Eric Gershwin
Journal:  Liver Int       Date:  2014-10-10       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.